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Abstract
Arsenic contamination of drinking water is a major public health issue in many countries, increasing risk for a wide array of
diseases, including cancer. There is inter-individual variation in arsenic metabolism efficiency and susceptibility to arsenic
toxicity; however, the basis of this variation is not well understood. Here, we have performed the first genome-wide
association study (GWAS) of arsenic-related metabolism and toxicity phenotypes to improve our understanding of the
mechanisms by which arsenic affects health. Using data on urinary arsenic metabolite concentrations and approximately
300,000 genome-wide single nucleotide polymorphisms (SNPs) for 1,313 arsenic-exposed Bangladeshi individuals, we
identified genome-wide significant association signals (P,5610
28) for percentages of both monomethylarsonic acid (MMA)
and dimethylarsinic acid (DMA) near the AS3MT gene (arsenite methyltransferase; 10q24.32), with five genetic variants
showing independent associations. In a follow-up analysis of 1,085 individuals with arsenic-induced premalignant skin
lesions (the classical sign of arsenic toxicity) and 1,794 controls, we show that one of these five variants (rs9527) is also
associated with skin lesion risk (P=0.0005). Using a subset of individuals with prospectively measured arsenic (n=769), we
show that rs9527 interacts with arsenic to influence incident skin lesion risk (P=0.01). Expression quantitative trait locus
(eQTL) analyses of genome-wide expression data from 950 individual’s lymphocyte RNA suggest that several of our lead
SNPs represent cis-eQTLs for AS3MT (P=10
212) and neighboring gene C10orf32 (P=10
244), which are involved in C10orf32-
AS3MT read-through transcription. This is the largest and most comprehensive genomic investigation of arsenic metabolism
and toxicity to date, the only GWAS of any arsenic-related trait, and the first study to implicate 10q24.32 variants in both
arsenic metabolism and arsenical skin lesion risk. The observed patterns of associations suggest that MMA% and DMA%
have distinct genetic determinants and support the hypothesis that DMA is the less toxic of these two methylated arsenic
species. These results have potential translational implications for the prevention and treatment of arsenic-associated
toxicities worldwide.
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Introduction
Over 100 million individuals worldwide are exposed to arsenic
through drinking water, including approximately 56 million
people in Bangladesh [1] and 13 million in the United States
[2]. Arsenic is a class I human carcinogen, and chronic exposure
to high levels of arsenic (.300 mg/L) is associated with substantial
increased risk for a wide array of diseases including cancers of the
lung [3], bladder [4], liver [5], skin [6], and kidney [7,8], as well as
neurological [9,10] and cardiovascular [11] diseases. Emerging
evidence suggests that arsenic may have adverse effects on health
even at concentrations as low as 10–50 mg/L, as recent studies in
Bangladesh have observed dose-response relationships with
mortality [12,13] and arsenical skin lesion risk [14] in populations
with low to moderate arsenic exposure over many years. Arsenical
skin lesions are a classical sign of arsenic toxicity, an indicator of
susceptibility to arsenic-related disease, and a precursor to arsenic-
induced skin cancers [6]. Once individuals are chronically exposed
to arsenic, risk for arsenic-related diseases and mortality remains
high for several decades even after cessation of exposure [15,16].
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V and As
III, known
collectively as inorganic arsenic (iAs). Once consumed, iAs is
methylated using S-Adenosyl methionine (SAM) as the methyl
donor, producing monomethylarsonic acid (MMA) and then
dimethylarsinic acid (DMA). MMA is believed to be the more
toxic of these metabolites, with the DMA/MMA ratio showing an
inverse association with arsenic toxicity in several studies [17–20]
and DMA being more readily excreted in urine and expelled from
the body. Arsenic metabolite concentrations are often expressed as
percentages of all arsenic species present in urine (i.e., iAs%,
MMA%, DMA%) or as ratios that reflect methylation efficiency
(e.g., DMA%/MMA%, MMA%/iAs%).
There is considerable inter-individual variation in arsenic
metabolism, as some individuals are able to methylate, and thus
excrete, arsenic more efficiently than others [21,22]. Similarly,
because high inter-individual variability in toxicity is observed
among individuals with similar levels of exposure to arsenic,
genetic susceptibility factors for arsenical skin lesions are believed
to exist [23].
In light of the enormous global health impact of arsenic
exposure and the remarkable inter-individual variability in arsenic
metabolism and toxicity, we performed the first genome-wide
association study (GWAS) of common arsenic-related phenotypes.
We identified multiple genetic variants in the 10q24.32 region
near AS3MT (arsenite methyltransferase, previously known as
CYT19) that show robust associations with urinary concentrations
of arsenic metabolites, risk for arsenical skin lesions, and local gene
expression, including transcript levels of AS3MT.
Results
GWAS of arsenic metabolites
We assessed genome-wide associations for the three arsenic
metabolites measured in urine (iAs%, MMA%, and DMA%) using
high-quality data on 259,597 single-nucleotide polymorphisms
(SNPs) from 1,313 individuals randomly selected from a large
population-based cohort of Bangladeshi individuals exposed to a
wide range of arsenic concentrations through drinking water.
Associations were assessed using mixed linear models [24] to
account for existence of related individuals in our sample (Figure
S1). The strongest association signals, genome-wide, for both
DMA% and MMA% were in the 10q24.32 region (P,5610
28)
(Figures S2 and S3), which contains the AS3MT gene and
substantial LD spanning ,1 Mb (Figure S4).
For DMA%, the strongest 10q24.32 association was for rs9527
(P=2.7610
29; Figure 1). After conditioning on rs9527, a strong
residual association signal remained (rs11191527; P=8.0610
28), the
strength of which was weaker without adjustment for rs9527
(P=2.3610
25) due to mild LD between these SNPs (D9=0.26,
r
2=0.03 in our data; D9=0.27; r
2=0.03 inHapMap GIH). After
conditioningonbothSNPs,therewas very littleevidence of additional
association in the region. Analyses of imputed and measured
genotypes produced the same two association signals, but with
imputed SNPs rs3740394 and rs17115073 showing slightly stronger
association than rs9527 and rs11191527, respectively (Figure S5).
The strongest association observed for MMA% was rs4919694
(P=2.9610
28) (Figure 2). After conditioning on rs4919694,
residual association was still observed (rs4290163; P=7.0610
25).
This association is much weaker without adjustment for rs4919694
(P=0.03) due to LD between rs4919694 and rs4290163
(D9=0.80, r
2=0.09 in our data; D9=0.80, r
2=0.04 in HapMap
GIH). Aftern conditioning on both SNPs, residual association was
observed for rs11191659 (P=0.0009), a SNP in moderate LD with
rs9527, the top SNP from the %DMA analysis (D9=0.66,
r
2=0.23 in our data; D9=0.82, r
2=0.30 in HapMap GIH).
Conditioning on all three SNPs eliminated the 10q24.32
association signal. Imputation of unobserved genotypes in the
region did not reveal associations stronger than those observed for
the measured genotypes (Figure S6). Multivariate models for
%DMA and %MMA including all five of the above-mentioned
SNPs are described in Table 1. Outside of the 10q24.32 region,
there was no genome-wide significant (P,5610
28) association
signal for DMA% or MMA%.
The 10q24.32 association results for the DMA%/MMA% ratio
(the ‘‘secondary methylation index’’, log-transformed), were very
similar to the MMA% results, as these phenotypes were strongly
correlated (r=20.84; Table S1). Associations for 10q24.32 SNPs
with iAs% and MMA%/iAs% (the ‘‘primary methylation index’’
(PMI) log-transformed) were much weaker than for DMA% and
MMA%; The strongest association in the 10q24.32 region observed
for iAs% was rs9527 (P=0.0009) and no association of P,0.001
was observed for log(PMI). In genome-wide analyses of iAs% and
PMI, no SNP reached genome-wide significance (Figure S7).
Association of SNPs with skin lesions risk
Because variants influencing arsenic metabolism may alter
susceptibility to arsenic toxicity, we investigated the roles of
metabolite-associated SNPs in arsenic-induced premalignant skin
lesions, the hallmark of chronic arsenic toxicity. For our five lead
SNPs, we tested association with skin lesion status among 1,085
skin lesion cases and 1,794 population controls, using the
ROADTRIPS method that was developed for case-control
association testing in the presence of cryptic relatedness [25].
The rs9527 allele associated with decreased DMA% (A) was
associated with increased skin lesion risk (P=0.0005), consistent
with the hypothesis that DMA is less toxic than MMA (Table 2).
rs11191659 showed suggestive association (P=0.02), also consis-
tent with this hypothesis.
To confirm that these associations with skin lesions were due to
gene-arsenic interaction, we tested the interaction between rs9527
Author Summary
Exposure to arsenic through drinking water is a serious
public health issue in many countries, including Bangla-
desh and the United States. Although there is substantial
inter-individual variation in arsenic metabolism and
toxicity, the biological basis of this variation is not well
understood. Here, we have conducted the first genome-
wide association study of arsenic-related traits within a
unique population cohort of arsenic-exposed Bangladeshi
individuals. Using data on 1,313 well-characterized indi-
viduals, we identify multiple association signals for urinary
arsenic metabolite concentrations in the 10q24.32 regions,
near the AS3MT (arsenite methyltransferase) gene. In a
subsequent analysis of .2,000 individuals, we show for
the first time that variants that influence arsenic metab-
olism can also influence risk for arsenical skin lesions (the
classical sign of arsenic toxicity) through interaction with
arsenic exposure. Using array-based genome-wide gene
expression data, we show that several of our lead genetic
variants are associated with expression of AS3MT and
neighboring gene C10orf32, providing a potential mech-
anism by which 10q24.32 variants influence arsenic
metabolism and toxicity. Knowledge of variation in this
region and associated biological processes could be used
to develop intervention and pharmacological strategies
aimed at preventing large numbers of arsenic-related
deaths in arsenic-exposed populations.
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and 700 controls with prospectively-measured arsenic exposure
(measured in both water and urine at baseline, prior to skin lesion
incidence and arsenic mitigation efforts [26]). We found SNP-
arsenic interaction for both rs9527 (multiplicative interaction
P=0.01; additive interaction P=0.004) and rs11191659 (multi-
plicative interaction P=0.02; additive interaction P=0.001),
where water arsenic exposure showed stronger association with
skin lesions in the presence of the risk allele (Table 2 and Table
S2). There were no significant main effects for either of these SNPs
in the context of models that included SNP-arsenic interaction
terms.
For the subset of individuals with available genotype, arsenic
metabolite, and skin lesion data (82 cases, 1211 controls), DMA%
Figure 1. Multiple variants in the 10q24.32 region show independent associations with DMA% (n=1,313). P-values were generated
using mixed models adjusted for age, sex, and water arsenic concentration. The strongest associated SNP is labeled in each panel. Panel A shows the
overall association results. Panel B shows P-values from models that are adjusted for rs9527. Panel C shows P-values from models adjusted for both
rs9527 and rs11191527.
doi:10.1371/journal.pgen.1002522.g001
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rs9527 and skin lesions (accounting for 13% of the observed
association).
eQTL analyses of the 10q24.32 region
To investigate the role of our lead SNPs in gene regulation, used
genome-wide expression data derived from lymphocyte RNA
obtained at baseline for 950 participants (Illumina HumanHT-12
array) and examined SNP-expression associations for all 30 genes
in the 10q24.32 LD region (Table S3). Several of our lead SNPs
showed association with AS3MT expression at P,5610
25
(rs4919694, rs9527, rs4290163). However, after examining
associations for all SNPs in this region, C10orf32 intronic SNP
rs7096169 showed the strongest association with AS3MT
Figure 2. Multiple variants in the 10q24.32 region show independent associations with MMA% (n=1,313). P-values were generated
using mixed models adjusted for age, sex, and water arsenic concentration. The strongest associated SNP is labeled in each panel. Panel A shows the
overall association results. Panel B shows P-values from models that are adjusted for rs4919694. Panel C shows P-values from models adjusted for
both rs4919694 and rs4290163.
doi:10.1371/journal.pgen.1002522.g002
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212; Figure 3 and Figure S8), and conditioning
on rs7096169 eliminated the eQTL signal. rs7096169 was not one
of our lead SNPs, but it was associated with DMA% (P=0.001;
MMA% P=0.28). Interestingly, the rs9527 risk allele (A) was
associated with decreased C10orf32 expression (P=2.6610
241;
Figure S8), the strongest eQTL signal for C10orf32 expression in
theregion(Figure 3)andthestrongestgenome-wideeQTLeffectfor
rs9527 (Figure S9). C10orf32 is ,4 kb upstream of AS3MT, and
these genes are involved in C10orf32-AS3MT read-through
transcription, producing a transcript that is a candidate for
nonsense-mediated mRNA decay. Thus, it is possible that the
eQTL signal observed for C10orf32 represents a regulatory
mechanism that influences read-through transcript production.
After conditioning on rs9527, the residual eQTL signal was best
represented by rs11083790 (P=10
25). Conditioning on both SNPs
eliminated the eQTL signal. Interestingly, C10orf32 expression was
also associated with arsenic exposure (measured as total arsenic in
urine,collected at thesametimeas blood;P=0.001),while AS3MT
expression was not (P=0.37). None of our lead SNPs modified the
association between arsenic exposure and C10orf32 expression.
Our lead SNPs were also associated with USMG5 expression
(Table S3), a gene ,500 kb downstream of AS3MT, but these
associations appear to be due to moderate LD with downstream
variants showing very strong association with USMG5 expression
(e.g., rs12220267; P=10
2210; Figure S8).
Discussion
The role of AS3MT in arsenic metabolism has been described
[27], and several prior studies have evaluated associations between
candidate AS3MT variants arsenic-related traits in Bangladesh
and elsewhere [28–34]. A recent review [35] highlighted two
AS3MT SNPs, rs11191439 (Met287Thr) and rs3740393 (intro-
nic), as being consistently related to arsenic metabolism across
diverse populations. The most recent and comprehensive
Bangladeshi study of AS3MT SNPs [28] reported three associa-
tion signals for arsenic metabolites, best represented by HapMap3
SNPs rs1046778 (for MMA%), rs11191439 (DMA% and iAs%),
and rs3740390 (DMA% and iAs%), a proxy for rs3740393
(r
2=0.91). After imputation, we were able to replicate rs11191439
(DMA% P=4.2610
26; MMA% P=5.8610
27) and rs1046778
(MMA% P=8.9610
27; DMA% P=0.0002), which were strongly
correlated with lead SNPs rs4919694 (r
2=0.69) and rs4290163
(r
2=0.63), respectively. After conditioning on our lead SNPs, these
associations were no longer significant. The evidence for
rs3740390 was less convincing (DMA% P=0.54; MMA%
P=0.007), as this SNP was not strongly correlated with any of
our lead SNPs (Figure S10). We identified two novel 10q24.32
association signals, represented by rs9527 and rs11191527, which
were not strongly correlated with any previously-reported SNP
(Figure S10). These SNPs were likely missed in prior studies due to
limited coverage of the SNPs in this region.
The identities of the functional variants in this region remain
unclear. rs9527 lies in the 59 UTR of C10orf32, a transcription
factor binding region (GATA-1 and TAL1 (SC-12984)) and a
DNase hypersensitivity site. If causal, rs9527 could also exert its
effects through regulation of AS3MT-C10orf32 read-through
transcription. However, the LD block represented by rs9527
includes transcription factor binding site SNP rs12416687 and
miRNA SNPs rs11191401, rs12573077, rs7904252, and rs9527.
Detailed information on potential functional variants from
HapMap3 (GIH) for each of the 5 SNPs identified is contained
in Tables S4, S5, S6, S7, S8. However, genetic variation in this
Table 1. Multivariate associations between arsenic
metabolites and genotyped SNPs in the 10q24.32 region
showing the strongest univariate associations with DMA%
and MMA% (n=1,313).
DMA% MMA%
SNP (MA
a) MAF
b
Beta
coefficient P-value
Beta
coefficient P-value
rs9527 (A) 0.09 22.95 0.0002 0.86 0.05
rs11191527 (A) 0.16 2.16 4.4610
25 20.55 0.06
rs4919694 (G) 0.10 20.93 0.14 1.49 3.1610
25
rs4290163 (A) 0.43 0.26 0.50 20.65 0.003
rs11191659 (A) 0.05 22.07 0.02 1.08 0.04
Regression models including all five SNPs in a single model, adjusting for age,
sex, and water arsenic. All regressions were mixed models carried out using
EMMAX.
aMA, minor allele.
bMAF, minor allele frequency.
doi:10.1371/journal.pgen.1002522.t001
Table 2. Association between the 10q24.32 genotyped variants and arsenical skin lesion risk and SNP-arsenic interaction
estimates.
MAF Logistic regression
b ROADTRIPS
c Interaction with arsenic
d
SNP (MA
a)
Association with
arsenic metabolite
Cases
(n=1,085)
Controls
(n=1,794) OR CI P-value P-value
Water arsenic
P-value
Urine arsenic
P-value
rs9527 (A) QDMA% 0.108 0.076 1.42 1.16–1.72 0.0005 0.0005 0.004 0.02
rs11191527 (A) qDMA% 0.152 0.163 0.96 0.89–1.29 0.38 0.33 0.72 0.38
rs4919694 (G) qMMA% 0.103 0.098 1.07 0.89–1.29 0.46 0.60 0.87 0.34
rs4290163 (A) QMMA% 0.427 0.434 0.96 0.82–.112 0.59 0.62 0.99 0.23
rs11191659 (A) qMMA% 0.058 0.042 1.32 1.02–1.72 0.04 0.02 0.001 ,0.0001
aMA, minor allele.
bEach Logistic Regression model includes one SNP, adjusting for age and sex.
cThe ROADTRIPS case-control test does not allow multivariate modeling (i.e., no adjustments), but accounts for cryptic relatedness.
dInteraction P-values are from mixed linear models that account for relatedness among subjects. Interactions are on the additive scale and are calculated using data on
69 cases and incident 700 controls.
doi:10.1371/journal.pgen.1002522.t002
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rare variation), and the underlying functional variants may not be
present in HapMap3. It is also possible that the underlying causal
variants have implications for surrounding genes. For example,
rs4919694 and rs11191527 are intronic SNPs within the CNNM2
gene, which is involved in magnesium reabsorption by the kidney
[36]. It is possible that magnesium and iAs interact [37,38],
influencing the amount of free arsenic available for methylation.
To our knowledge, this study is the largest genetic association
study of arsenic metabolites to date, the only GWAS of arsenic-
related traits, the first study to implicate 10q24.32 SNPs in both
arsenic metabolism and arsenical skin lesion risk, and one of the
earliest GWAS conducted in the developing country setting. Our
results suggest that MMA% and DMA% have distinct genetic
determinants and highlight the importance of conditional analyses,
as LD among alleles with opposing effects can mask associations in
univariate analyses. The associations observed in this study are
likely due to the effects of unmeasured, potentially rare variants in
LD with the measured SNPs and/or substantial allelic heteroge-
neity, whereby multiple 10q24.32 variants influence arsenic
metabolism.
Considering the substantial LD in this region [39], the variation
in allele frequencies and LD patterns among the various arsenic-
exposed populations under study [40], and the apparent allelic
heterogeneity with respect to arsenic metabolism, future DNA
sequencing studies are needed to help identify causal variants in
the 10q24.32 region. Identifying these variants will help clarify the
links between the association signals observed for %DMA,
Figure 3. Variants in the 10q24.32 region are associated with transcript levels of AS3MT and C10orf32. C10orf32 is ,4 kb from AS3MT
and involved in C10orf32-AS3MT read-through transcription. P-values were generated using mixed linear models adjusted for age and sex.
doi:10.1371/journal.pgen.1002522.g003
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signals appear largely independent in our dataset, but perhaps
there are underlying causal variants that influence all of these
phenotypes. Developing a better understanding the effects of
functional variation related to AS3MT will also provide a more
nuanced understanding of the biology of arsenic methylation,
which can in turn help us better understand how variation in
methylation efficiency affects health. Finally, knowledge of this
causal variation and the methylation processes that they influence
could potentially be exploited for intervention strategies that aim
to prevent large numbers of deaths arsenic-exposed populations,
by defining susceptibility subgroups and exploiting the biological
processes uncovered by genomics for developing pharmacological
treatments.
Materials and Methods
Study descriptions
The DNA samples genotyped in this study were obtained at
baseline recruitment from individuals participating in one of the
following studies: The Health Effects of Arsenic Longitudinal
Study (HEALS) [41] or the Bangladesh Vitamin E and Selenium
Trial (BEST) [42]. GWAS analyses of arsenic metabolites were
conducted using urinary arsenic metabolite and SNP data on
1,313 individuals randomly selected from the HEALS study.
Analyses of skin lesion data were conducted using genotype data
from 1,085 skin lesion cases and 1,794 controls drawn from both
studies, including the 1,313 HEALS individuals with metabolite
data. Skin lesion cases included individuals with keratosis,
melanosis, and leukomelanosis. Gene expression analyses were
based on lymphocyte RNA extracted at baseline recruitment for
the first 950 BEST participants. A summary of these overlapping
sets of samples is provided in Figure S11.
The Health Effects of Arsenic Longitudinal Study (HEALS [41]) is a
prospective investigation of health outcomes associated with
arsenic exposure through drinking water in a cohort of adults in
Araihazar, Bangladesh, a rural area east of the capital city, Dhaka.
Between October 2000 and May 2002, we recruited healthy
married individuals (age 18–75 years) who were residents of the
study area for at least five years and primarily consumed drinking
water from a local well. We enumerated 65,876 individuals
residing in Araihazar, from which we identified a sampling frame
of 14,828 eligible residents. Of these 14,828 individuals, 11,746
men and women were enrolled. During 2006–2008, additional
recruitment of 8,287 participants from the same underlying source
population expanded the cohort size to over 20,000 individuals.
All 5,966 wells in the study area were tested for arsenic using
graphite furnace atomic absorption spectrometry and individuals
reported the primary well from which they drank. At baseline,
trained study physicians, blinded to the arsenic measurements,
conducted in-person interviews and clinical evaluations and
collected spot urine and blood samples from participants in their
homes using structured protocols. Similar in-person follow-up
interviews were conducted biennially for the entire cohort during
the following periods: follow-up 1 during September 2002 to May
2004, follow-up 2 during June 2004 to August 2006, and follow-up
3 during January 2007 to February 2009. At baseline and each
follow-up interview, a structured protocol was used to ascertain
skin lesions by the study physicians, who had undergone training
for the detection and diagnosis of skin lesions [43]. The study
protocol was approved by the Institutional Review Boards of The
University of Chicago, Columbia University, and the Bangladesh
Medical Research Council. Informed consent was obtained from
all participants.
The Bangladesh Vitamin E and Selenium Trial (BEST) is a 262
factorial randomized chemoprevention trial evaluating the long-
term effects of vitamin E and selenium supplementation on non-
melanoma skin cancer (NMSC) risk. BEST participants are
residents of Araihazar (the same geographic area as HEALS
participants with 132 overlapping participants), Matlab, and
surrounding areas. BEST uses many of the same study protocols
as does HEALS, especially arsenic exposure assessment and
biospecimen collection protocols. All participants were required to
have existing arsenic-related skin lesions to be eligible. A total of
7,000 individuals have been randomized to one of the four
treatment arms: vitamin E only (100 IU/day), L-selenomethionine
only (200 mg/day), both vitamin E and selenium, and placebo.
Participants have been actively followed for 6 years and systematic
ascertainment of histopathologically-confirmed NMSC has been
conducted (including BCC and SCC). For all participants,
biological samples, including all fractions of blood including
DNA and RNA, urine, toenails, and tumor samples have been
collected at baseline, along with clinical and covariate data,
creating a biological and data repository that is available for
research purposes. The study protocol was approved by the
Ethical Review Committee of International Center for Diarrheal
Disease Research, Bangladesh, the Bangladesh Medical Research
Council, and the Institutional Review Boards of The University of
Chicago and Columbia University. Informed consent was
obtained from all participants.
In each study, urinary arsenic was measured using graphite
furnace atomic absorption spectrometry in a single laboratory
[44]. Urinary creatinine was measured by a colorimetric
diagnostics kit (Sigma, St Louis, MO, USA). Total urinary arsenic
concentration was divided by creatinine to obtain creatinine-
adjusted total arsenic concentration (mg/g creatinine) [45].
Urinary arsenic metabolites (arsenobetaine, arsenocholine, arse-
nite, arsenate, monomethylarseonous acid, and dimethylarsenic
acid) were distinguished as described by Ahsan et al. [17], using a
high-performance liquid chromatography method for separation
of arsenic metabolites, followed by detection using inductively
coupled plasma-mass spectrometry with dynamic reaction cell.
The percentage of iAs, MMA and DMA in total arsenic was
calculated after subtracting asenobetaine and arsenocholine (i.e.,
nontoxic organic arsenic from dietary sources). Because these
metabolites lie on the same biological pathway and are expressed
as a percentage of arsenic species, their values show substantial
correlation (Table S1).
Genotyping and quality control
For BEST samples, DNA extraction was carried out from the
whole blood using the QIAamp 96 DNA Blood Kit (cat # 51161)
from Qiagen, Valencia, USA. For HEALS samples, DNA was
extracted from clot blood using Flexigene DNA kit (Cat # 51204)
from Qiagen. Concentration and quality of all extracted DNA
were checked by Nanodrop 1000. As starting material, 250 ng of
DNA was used on the Illumina Infinium HD SNP array according
to Illumina’s protocol. Samples were processed on HumanCy-
toSNP-12 v2.1 chips with 299,140 markers and read on the
BeadArray Reader. Image data was processed in BeadStudio
software to generate genotype calls.
Prior to genotype QC, our genotype data consisted of 2,920
samples typed for 299,140 SNPs. First, we removed DNA samples
with very poor call rates (,90%; n=8) and SNPs that were poorly
called (,90%) or monomorphic (n=39,276). Individuals with
gender mismatches were removed (n=10), as were technical
replicate DNA samples run to assure high genotyping accuracy
(n=21). No individuals had outlying autosomal heterozygosity or
GWAS of Arsenic Metabolism and Toxicity
PLoS Genetics | www.plosgenetics.org 7 February 2012 | Volume 8 | Issue 2 | e1002522inbreeding values. After inspecting distributions of SNP and
samples call rates, we excluded samples with call rates ,97%
(n=2) and SNPs with call rates ,95% (n=103). SNPs with HWE
p-values,10
27 were excluded (n=164). This QC resulted in
2,879 individuals with high-quality genotype data for 259,597
SNPs. All QC was performed using PLINK [46].
Gene expression
RNA was extracted from mononuclear cells preserved in buffer
RLT, stored at 286uC using RNeasy Micro Kit (cat# 74004)
from Qiagen, Valencia, USA. Concentration and quality of all
extracted RNA were checked on Nanodrop 1000. cRNA synthesis
was done from 250 ng of RNA using Illumina TotalPrep 96 RNA
Amplification kit. As recommended by Illumina we used 750 ng of
cRNA on HumanHT-12-v4 for gene expression. The chip
contains a total of 47,231 probes covering 31,335 genes.
Statistical analyses and software tools
Pair-wise kinship coefficients were estimated using PLINK [46]
and their distribution is shown in Figure S1. To assess population
structure that was unrelated to the relative pairs present in our
dataset, we removed one individual from each related pair
(kinship coefficient .0.05) and assessed population structure in
this dataset of 403 individuals using principal components
analysis as implemented in EIGENSTRAT [47]. We found very
little evidence of population stratification (Figure S12), with the
eigenvalues from the first ten principle components being
between 1.123 and 1.184. All SNP association tests for urinary
metabolites were conducted using a mixed model that accounted
for cryptic relatedness as implemented in EMMAX [24] (rather
than principle components), adjusting for water arsenic, sex, and
age. All regional association plots were generated using
LocusZoom [48]. Association testing for skin lesion status was
conducting using PLINK [46] and the ROADTRIPS [25]
software developed for case-control association testing in samples
with unknown population and pedigree structure. We conducted
local imputation for the 10q24.32 region using MACH, the GIH
reference panel, and imputation parameters suggested by the
developers [49]. The estimated genotype and allele error rates
were 0.034 and 0.017, respectively. LD structure in the 10q24.32
region was visualized using Haploview [50]. Information on the
potential functional consequences of SNPs in the 10q24.32
regions was obtained using the NIEHS’s SNPinfo Web Server
[51]. Interaction analyses was conducted using only HEALS
incident cases (n=69) and controls (n=701). For BEST
participants and some HEALS participants arsenic exposure
(based on water and urine) was not measured prior to arsenic
mitigation efforts [26], so the measured exposure status for these
individuals is not likely to reflect long-term arsenic exposure
status. Interactions were tested using the SAS 9.2 PROC MIXED
procedure, using the ‘‘bn’’ matrix derived using EMMAX. To
assess mediation of the association between SNPs and skin
lesions, we used the ‘‘proportion explained’’ (PE) equation for
odds ratios (PEOR=(OR xy2ORxy|m)/(ORxy21) where x is an
exposure, y is a binary outcome, and m is a potential mediating
factor [52]). Genome-wide eQTL analysis for our five lead SNPs
was performed using the significance of microarray method as
implemented in BRB Array Tools. Promising eQTL effects were
then examined using EMMAX as described above, treating the
expression values as a quantitative trait. In a similar fashion,
arsenic exposure was tested for association with expression traits
of interest and for interaction with SNPs in relation to expression
traits using PROC MIXED.
Supporting Information
Figure S1 Distribution of all pair-wise kinship coefficients
among 2,879 Bangladeshi individuals with measured genome-
wide SNP data. Kinship values are truncated at 0.05. The
observed clusters of observations centered at 0.5 0.25, and 0.125
represent full siblings or parent-offspring, half siblings, and, and
first cousins pairs, respectively. One individual from each pair of
twins or duplicate samples (kinship coefficient of 1.0) was removed
from the analysis dataset.
(TIF)
Figure S2 GWAS Results for DMA% (including Manhattan
plot, QQ plot, and the strongest associated SNPs).
(TIF)
Figure S3 GWAS Results for MMA% (including Manhattan
plot, QQ plot, and the strongest associated SNPs).
(TIF)
Figure S4 Summary of linkage disequilibrium (LD) in the
10q24.32 region. LD data for all SNPs in the GIH HapMap3
panel are shown above (A) and the data for SNPs typed in this
study are shown below (B). Dark red squares represent a D9 value
near 1 and white squares represent a D9 value near zero.
(TIF)
Figure S5 DMA% associations results for imputed and geno-
typed SNPs in the 10q24.32 region (n=1,313). P-values were
generated using mixed-models adjusted for age, sex, and water
arsenic concentration. The strongest associated SNP is labeled in
each panel. The top panel shows the overall association results.
The second panel shows P-values from models that are adjusted
for rs3740394. The third panel shows P-values from models
adjusted for both rs3740394 and rs17115073.
(TIF)
Figure S6 MMA% associations results for imputed and
genotyped SNPs in the 10q24.32 region (n=1,313). P-values were
generated using mixed-models adjusted for age, sex, and water
arsenic concentration. The strongest associated SNP is labeled in
each panel. The top panel shows the overall association results.
The second panel shows P-values from models that are adjusted
for rs4919694. The third panel shows P-values from models
adjusted for both rs4919694 and rs4290163.
(TIF)
Figure S7 Q-Q plots for genome-wide association scans of the
iAs% and the primary methylation index (PMI=MMA%/iAs%).
Results are based on 1,310 samples and 259,597 SNPs. The
EMMAX model is adjusted for sex and water arsenic.
(TIF)
Figure S8 Cis-eQTL signals in the 10q24.32 region. Expression
values for AS3MT, C10orf32, and USMG5 are shown by the
minor allele count for rs7096160, rs9527, and rs12220267,
respectively. Mean expression values are shown as dotted lines.
(TIF)
Figure S9 Association for our 5 lead SNPs with genome-wide
transcript levels. Genome-wide eQTL analysis was performed
using the Significance of Microarray method as implemented in
BRB Array Tools. The first and second most strongly associated
transcripts (in red) are C10orf32 and USMG5, respectively. Both
are in the 10q24.32 region.
(TIF)
Figure S10 Linkage Disequilibrium between lead SNPs and
previously reported variants. Our lead SNPs are shown in boxes
GWAS of Arsenic Metabolism and Toxicity
PLoS Genetics | www.plosgenetics.org 8 February 2012 | Volume 8 | Issue 2 | e1002522and the variants representing the signals previously reported in a
Bangladeshi study (Engstrom et al. [30]) are shown in circles.
(TIF)
Figure S11 An overview of the participants and samples used in
this work.
(TIF)
Figure S12 Scatter plot of the first two principle components for
403 unrelated study participants (no pair-wise kinship val-
ue.0.05).
(TIF)
Table S1 Pair-wise correlations among the arsenic-related
urinary phenotypes examined in this study (n=1,333).
(DOCX)
Table S2 Regression models for interaction between arsenic
exposure and rs9257 in relation to skin lesion risk (69 skin lesion
cases, 701 controls).
(DOCX)
Table S3 P-values from association test for our 5 lead 10q24.32
SNPs and expression values for all genes in the 10q24.32 LD
region (n=950 individuals).
(DOCX)
Table S4 Functional information for SNPs in LD with rs9527.
(PDF)
Table S5 Functional information for SNPs in LD with
rs11191527.
(PDF)
Table S6 Functional information for SNPs in LD with
rs4919694.
(PDF)
Table S7 Functional information for SNPs in LD with
rs3740394.
(PDF)
Table S8 Functional information for SNPs in LD with
rs11191659.
(PDF)
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